ElectroCore Inc (ECOR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$8.80+4.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ECOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -47.0% |
| Our one-year growth estimate | diamond | 34.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 81.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
ECOR — CEO transition
Dated 2026-09-09
CEO — Joshua S. Lev, Michael Fox: Two existing senior executives (Interim President/CFO and COO) were promoted to co-CEO roles, representing a significant internal leadership restructuring rather than a departure.
Why it matters: The VA is electroCore's largest growth driver. VA sales growth slowed from 26% in Q1 to 11% in Q2.
Supportive ifQ3 VA gammaCore sales rise year over year, and the number of VA patients served grows from about 16,400.
Worry ifQ3 VA gammaCore sales fall year over year, or the reported patient count stays at or below about 16,400.
Why it matters: The company still loses money on this measure. Smaller losses would support its goal of positive adjusted EBITDA by Q3 2027.
Supportive ifQuarterly adjusted EBITDA loss falls below $1.8 million. It then reaches zero or better by Q3 2027.
Worry ifQuarterly adjusted EBITDA loss rises above $1.8 million, or the goal shifts past Q3 2027.
Why it matters: Joshua Lev and Mike Fox became co-CEOs in September. Their shared work on sales and company results is an early test of the new structure.
Watch forAt the next earnings call, both co-CEOs remain in place and report progress on sales growth or new sales channels.
Also watch forThe company announces that a co-CEO is leaving. Or it changes its shared leadership structure.
Why it matters: Sales and marketing costs rose year over year in Q2. The new plan targets lower sales costs by the end of 2027.
Supportive ifBy the end of 2027, sales and marketing costs move toward 54% of revenue. Incentive costs move toward 27% of prescription revenue.
Worry ifBy the end of 2027, sales and marketing costs stay above 54% of revenue. Or incentive costs stay near or above 35% of prescription revenue.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$277 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $808 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,415 loss on $10,000 · 44.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Quell sales reached $1.3 million in Q2, up about 700% from last year. Continued growth would show the new product line is gaining sales.
Supportive ifQ3 Quell sales exceed $1.3 million, with higher sales than Q2.
Worry ifQ3 Quell sales fall below $1.3 million, or management reports that demand is weaker.
Why it matters: Management raised its 2026 sales goal to over 30% growth. Q3 results are the next check on that goal.
Supportive ifOn the November 4, 2026, earnings call, management keeps its goal above 30% growth and reports Q3 sales that support it.
Worry ifManagement lowers its 2026 sales goal below 30% growth or reports Q3 sales that no longer support it.